| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.001 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.16 | 0.001 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.099 | 0.001 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |